Cg Oncology, Common Stock Analysis
| CGON Stock | 34.75 0.65 1.91% |
CG Oncology, Common is undervalued with Real Value of 42.88 and Hype Value of 34.12. The main objective of CG Oncology, stock analysis is to determine its intrinsic value, which is an estimate of what CG Oncology, Common is worth, separate from its market price. There are two main types of CG Oncology,'s stock analysis: fundamental analysis and technical analysis.
The CG Oncology, stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. CG Oncology, is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. CGON Stock trading window is adjusted to America/New York timezone.
CGON |
CGON Stock Analysis Notes
About 92.0% of the company shares are held by institutions such as insurance companies. The book value of CG Oncology, was currently reported as 7.95. The company recorded a loss per share of 15.87. CG Oncology, Common had not issued any dividends in recent years. For more info on CG Oncology, Common please contact Arthur Kuan at 949 409 3700 or go to https://cgoncology.com.CG Oncology, Common Investment Alerts
| CG Oncology, Common has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 204 K. Net Loss for the year was (48.61 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| CG Oncology, generates negative cash flow from operations | |
| CG Oncology, Common has a frail financial position based on the latest SEC disclosures | |
| Over 92.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: NRG Energy, Inc. Given Consensus Recommendation of Moderate Buy by Analysts |
CGON Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.31 B.Technical Drivers
As of the 30th of November, CG Oncology, owns the Coefficient Of Variation of 28784.4, market risk adjusted performance of 0.0018, and Standard Deviation of 2.74. CG Oncology, Common technical analysis gives you the methodology to make use of past data patterns to determine a pattern that approximates the direction of the firm's future prices.CG Oncology, Common Price Movement Analysis
The output start index for this execution was nine with a total number of output elements of fifty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. CG Oncology, middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for CG Oncology, Common. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
CG Oncology, Common Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CG Oncology, insiders, such as employees or executives, is commonly permitted as long as it does not rely on CG Oncology,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases CG Oncology, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Corleen Roche over three weeks ago Acquisition by Corleen Roche of 93600 shares of CG Oncology, at 36.63 subject to Rule 16b-3 | ||
Song Hong Fang over a month ago Acquisition by Song Hong Fang of 15600 shares of CG Oncology, at 36.63 subject to Rule 16b-3 | ||
Decheng Capital Global Life Sciences Fund Iv Lp over six months ago Conversion by Decheng Capital Global Life Sciences Fund Iv Lp of 3628198 shares of CG Oncology, | ||
Bellete Ambaw over six months ago CG Oncology exotic insider transaction detected |
CG Oncology, Outstanding Bonds
CG Oncology, issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. CG Oncology, Common uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most CGON bonds can be classified according to their maturity, which is the date when CG Oncology, Common has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
CG Oncology, Predictive Daily Indicators
CG Oncology, intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of CG Oncology, stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
CG Oncology, Forecast Models
CG Oncology,'s time-series forecasting models are one of many CG Oncology,'s stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary CG Oncology,'s historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding CG Oncology, to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Share Portfolio Now
Share PortfolioTrack or share privately all of your investments from the convenience of any device |
| All Next | Launch Module |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CG Oncology, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CG Oncology,. If investors know CGON will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CG Oncology, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of CG Oncology, Common is measured differently than its book value, which is the value of CGON that is recorded on the company's balance sheet. Investors also form their own opinion of CG Oncology,'s value that differs from its market value or its book value, called intrinsic value, which is CG Oncology,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CG Oncology,'s market value can be influenced by many factors that don't directly affect CG Oncology,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CG Oncology,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if CG Oncology, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CG Oncology,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.